Coverage of Travere Therapeutics was transferred to Citi analyst Yigal Nochomovitz, who raised the firm’s price target on Travere to $14 from $10 and kept a Buy rating on the shares, following a Q4 earnings report that held “no major surprises.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22)
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- TVTX Upcoming Earnings Report: What to Expect?
- Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
- Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
